QTRX vs. LAB, EYPT, PACB, CTKB, NAUT, AKYA, SLN, PRME, CVAC, and CSTL
Should you be buying Quanterix stock or one of its competitors? The main competitors of Quanterix include Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Pacific Biosciences of California (PACB), Cytek Biosciences (CTKB), Nautilus Biotechnology (NAUT), Akoya Biosciences (AKYA), Silence Therapeutics (SLN), Prime Medicine (PRME), CureVac (CVAC), and Castle Biosciences (CSTL). These companies are all part of the "medical" sector.
Quanterix (NASDAQ:QTRX) and Standard BioTools (NASDAQ:LAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
Quanterix received 264 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 61.66% of users gave Quanterix an outperform vote.
In the previous week, Quanterix had 17 more articles in the media than Standard BioTools. MarketBeat recorded 23 mentions for Quanterix and 6 mentions for Standard BioTools. Quanterix's average media sentiment score of 0.82 beat Standard BioTools' score of -0.19 indicating that Quanterix is being referred to more favorably in the media.
86.5% of Quanterix shares are held by institutional investors. Comparatively, 53.7% of Standard BioTools shares are held by institutional investors. 6.9% of Quanterix shares are held by company insiders. Comparatively, 53.1% of Standard BioTools shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Quanterix has higher revenue and earnings than Standard BioTools. Quanterix is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Quanterix presently has a consensus target price of $30.60, suggesting a potential upside of 77.70%. Standard BioTools has a consensus target price of $3.58, suggesting a potential upside of 41.63%. Given Quanterix's stronger consensus rating and higher possible upside, equities analysts clearly believe Quanterix is more favorable than Standard BioTools.
Quanterix has a net margin of -28.82% compared to Standard BioTools' net margin of -70.98%. Quanterix's return on equity of -10.39% beat Standard BioTools' return on equity.
Quanterix has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Standard BioTools has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.
Summary
Quanterix beats Standard BioTools on 14 of the 19 factors compared between the two stocks.
Get Quanterix News Delivered to You Automatically
Sign up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Quanterix Competitors List
Related Companies and Tools
